Revolution Medicines Advances Daraxonrasib Pancreatic Cancer Trial
Event summary
- Revolution Medicines initiated enrollment in Phase 3 trial RASolute 304, evaluating daraxonrasib in patients with resectable pancreatic ductal adenocarcinoma (PDAC) following adjuvant chemotherapy.
- The trial aims to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations.
- Daraxonrasib is a RAS(ON) multi-selective inhibitor, targeting mutations including G12X, G13X, and Q61X.
- This is one of four Phase 3 trials currently evaluating daraxonrasib, with three focused on PDAC and one on non-small cell lung cancer.
The big picture
Pancreatic cancer represents a significant unmet medical need with limited treatment options and a dismal five-year survival rate of only 3%. Revolution Medicines' focus on RAS-addicted cancers, a common feature in PDAC, positions daraxonrasib as a potential breakthrough therapy. The success of RASolute 304 will be critical for validating the company's RAS(ON) inhibitor platform and its broader oncology pipeline.
What we're watching
- Clinical Efficacy
- The trial's primary endpoint, disease-free survival, will be a key indicator of daraxonrasib's potential to meaningfully impact PDAC outcomes, given the disease's poor prognosis.
- Regulatory Pathway
- Success in RASolute 304 will be crucial for Revolution Medicines to secure regulatory approval for daraxonrasib, potentially opening up a significant market opportunity in a disease with high unmet need.
- Competitive Landscape
- The trial's results will be compared against standard observation, and the emergence of competing RAS inhibitors could impact daraxonrasib's market share and pricing strategy.
Related topics